Lisa D Pedicone
Overview
Explore the profile of Lisa D Pedicone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuwelker S, Tsai E, Kuo L, Kim J, Van Frank T, Mitchell R, et al.
Medicine (Baltimore)
. 2023 Jul;
102(30):e34183.
PMID: 37505173
Approved direct-acting antiviral (DAA) regimens against hepatitis C virus (HCV) can cure nearly all patients; however, socioeconomic disparities may impact access and outcome. This study assesses socioeconomic factors, differences in...
2.
Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, et al.
Medicine (Baltimore)
. 2019 Jul;
98(26):e16254.
PMID: 31261592
The aim of this study was to obtain real-world, US, observational data on the effect of baseline resistance-associated substitutions (RASs) on achieving sustained virologic response (SVR) in hepatitis C (HCV)...
3.
Kugelmas M, Pedicone L, Lio I, Simon S, Pietrandoni G
Gastroenterol Hepatol (N Y)
. 2017 Apr;
13(2):98-104.
PMID: 28450816
Approximately half of adults with hepatitis C in the United States do not know their infection status, and the majority of persons who know they are positive for hepatitis C...
4.
Vierling J, Zeuzem S, Poordad F, Bronowicki J, Manns M, Bacon B, et al.
J Hepatol
. 2014 Apr;
61(2):200-9.
PMID: 24747798
Background & Aims: HCV-infected cirrhotics may urgently need therapy but are often under-represented in clinical trials resulting in limited data to guide their management. We performed a meta-analysis of well-compensated...
5.
Melia M, Brau N, Poordad F, Lawitz E, Shiffman M, McHutchison J, et al.
Clin Infect Dis
. 2014 Jan;
58(7):960-9.
PMID: 24399086
Background: Myelosuppression due to pegylated interferon (peg-IFN) is common during treatment for hepatitis C virus. The relationship between infection risk and decreases in leukocyte lines, however, is not well established....
6.
Vierling J, Davis M, Flamm S, Gordon S, Lawitz E, Yoshida E, et al.
J Hepatol
. 2013 Dec;
60(4):748-56.
PMID: 24362076
Background & Aims: Boceprevir with peginterferon/ribavirin (BOC/PR) leads to significantly higher sustained virological response (SVR) rates in patients with chronic hepatitis C and partial response or relapse after prior treatment...
7.
Gordon S, Reddy K, Jacobson I, Poordad F, Bronowicki J, Bacon B, et al.
J Clin Gastroenterol
. 2013 Nov;
48(5):435-43.
PMID: 24177376
Background: Baseline viral load is a predictor of treatment outcome in patients with hepatitis C virus (HCV) infection receiving peginterferon and ribavirin. The impact of baseline viral load on sustained...
8.
Manns M, McCone Jr J, Davis M, Rossaro L, Schiff E, Shiffman M, et al.
Liver Int
. 2013 Oct;
34(5):707-19.
PMID: 24118703
Background & Aims: Triple therapy with peginterferon/ribavirin (PR) plus an NS3 protease inhibitor has emerged as the standard-of-care for patients with chronic hepatitis C genotype-1. We provide a detailed safety...
9.
Jazwinski A, Clark P, Thompson A, Gordon S, Lawitz E, Noviello S, et al.
Pharmacogenet Genomics
. 2013 Sep;
23(11):619-23.
PMID: 24061202
Introduction: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving...
10.
Poordad F, Lawitz E, Reddy K, Afdhal N, Hezode C, Zeuzem S, et al.
Gastroenterology
. 2013 Aug;
145(5):1035-1044.e5.
PMID: 23924660
Background & Aims: Treatment of hepatitis C virus (HCV) infection with boceprevir, peginterferon, and ribavirin can lead to anemia, which has been managed by reducing ribavirin dose and/or erythropoietin therapy....